PepsiCo, Inc. vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines PepsiCo, Inc. and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching PepsiCo, Inc. on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between PepsiCo, Inc. and F. Hoffmann-La Roche AG is widest.

On the headline numbers, PepsiCo, Inc. reports annual revenue of $93.9B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $205.0B and $327.5B. PepsiCo, Inc. is headquartered in United States and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.

PepsiCo, Inc.: PepsiCo is often framed through the cola wars, but the Frito-Lay system is the real structural engine. The 1965 merger created a company that could negotiate with retailers using both snacks and beverages, turning distribution breadth into an economic moat.

F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.

PepsiCo, Inc. and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between PepsiCo, Inc. and F. Hoffmann-La Roche AG.

PepsiCo, Inc. business model: PepsiCo makes money from convenient foods, beverages, concentrates, foodservice, licensing, and international packaged-food operations. The company sells finished products through company-owned and third-party distribution, and it benefits from direct-store-delivery strength in snacks and beverages.

F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of PepsiCo, Inc. stack up against those of F. Hoffmann-La Roche AG.

PepsiCo, Inc. competitive advantage: PepsiCo advantage comes from the combination of Frito-Lay scale, beverage brands, global distribution, direct-store delivery, product breadth, retailer relationships, and marketing investment.

F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.

Future prospects matter as much as current results. The growth strategies below explain how PepsiCo, Inc. and F. Hoffmann-La Roche AG each plan to expand from here.

PepsiCo, Inc. growth strategy: PepsiCo strategy centers on international growth, productivity, brand restages, zero-sugar beverages, functional hydration, convenient foods, and portfolio renovation. Steve Schmitt became CFO effective November 10, 2025, adding new finance leadership for the next phase of cost discipline.

F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.

A closer look at the financial trajectory of PepsiCo, Inc. and F. Hoffmann-La Roche AG rounds out the comparison.

PepsiCo, Inc.: PepsiCo reported $93.925 billion of FY2025 net revenue, up from $91.854 billion in FY2024 and $91.471 billion in FY2023. FY2025 net income attributable to PepsiCo was $8.240 billion. PepsiCo employed approximately 306,000 people worldwide as of December 27, 2025.

F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.